Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALPL | P05186 | 5/20 | 0.43 |
| ▸ | ALPI | P09923 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20403480 | 0.74 | GRIN2A (0.63) | SMN1; SMN2KDM4EPOLBLMNAALDH1A1 | |
| SCHEMBL246533 | 0.74 | CYP1A2 (0.51) | SMN1; SMN2KDM4EPOLBLMNAALDH1A1 | |
| SCHEMBL13461925 | 0.73 | ALDH1A1 (0.62) | SMN1; SMN2KDM4EPOLBLMNAALDH1A1 | |
| SCHEMBL10998360 | 0.71 | ALDH1A1 (0.49) | SMN1; SMN2KDM4EPOLBLMNAALDH1A1 | |
| SCHEMBL28878659 | 0.71 | ALDH1A1 (0.49) | SMN1; SMN2KDM4EPOLBLMNAALDH1A1 | |
| SCHEMBL29758447 | 0.70 | ALPI (0.49) | ALDH1A1ALPLALPI | |
| SCHEMBL29963384 | 0.70 | ALDH1A1 (0.48) | SMN1; SMN2KDM4EPOLBLMNAALDH1A1 | |
| SCHEMBL9215131 | 0.70 | ALDH1A1 (0.62) | SMN1; SMN2KDM4EPOLBLMNAALDH1A1 | |
| SCHEMBL15131088 | 0.70 | POLB (0.48) | SMN1; SMN2KDM4EPOLBLMNAALDH1A1 | |
| SCHEMBL1340803 | 0.68 | NPC1 (0.41) | SMN1; SMN2POLBLMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988400-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2018-06-05 | — | — | US | claimed |
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | AMGEN INC. (US) | 2025-10-21 | — | — | US | disclosed |
| CN-118161500-A | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | 安进公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114728167-B | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | 安进公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-11512097-B2 | Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-4065223-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-114728167-A | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | 安进公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210221824-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210221824-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210188874-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188874-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021108408-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108408-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| EP-3055315-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015052226-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512097-B2 | Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | SMN1; SMN2 2863/4885KDM4E 954/4885POLB 1910/4885 |
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | SCD5, SCD, FADS2 | SMN1; SMN2 2717/4885KDM4E 1019/4885POLB 1794/4885 |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | SCD5, SCD, FADS2 | SMN1; SMN2 2717/4885KDM4E 1019/4885POLB 1794/4885 |
| US-20210221824-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | SCD5, SCD, FADS2 | SMN1; SMN2 2863/4885KDM4E 954/4885POLB 1910/4885 |
| US-20210188874-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | SCD5, SCD, FADS2 | SMN1; SMN2 2863/4885KDM4E 954/4885POLB 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.